Given the reduction in the clinical trial activity of Aptevo Therapeutics Inc., on October 22, 2019, Scott Stromatt, M.D. agreed to change his status from an employee to a consultant starting on November 1, 2019 and thus resigned as the Chief Medical Officer and SVP, Clinical Development & Medical Affairs of the company, effective close of business on October 31, 2019. Dr. Stromatt will consult for the company for a period of 12 months to provide oversight over the company's ongoing clinical trial for APVO436, the company's lead ADAPTIR bispecific antibody candidate, and provide assistance with respect to other clinical and medical affairs matters as needed.